SCHEMBL3975741

SCHEMBL3975741

N#Cc1c(O)ccc(C(=O)OC(=O)c2occc2-c2cccc(OCCc3ccccc3)c2)c1C(=O)NN

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.36
KISS1R Q969F8 2/20 0.34
PLA2G10 O15496 1/20 0.34
PLA2G2A P14555 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
F9 P00740 1/20 0.33
FFAR1 O14842 1/20 0.33
PPARG P37231 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977732 0.93 GUSB (0.39) NR1H4KDM4EALDH1A1HTTGAA
SCHEMBL3976427 0.90 USP2 (0.38) NR1H4KDM4EALDH1A1HTTLMNA
SCHEMBL3973253 0.90 MEN1 (0.36) KISS1RKDM4EALDH1A1SMN1; SMN2
SCHEMBL3974737 0.87 ALDH1A1 (0.35) ALDH1A1
SCHEMBL3976175 0.87 FABP1 (0.31) KISS1R
SCHEMBL3975376 0.87 NR1H4 (0.38) NR1H4SIRT2PLA2G10PLA2G2AKDM4E
SCHEMBL3974765 0.87 ALDH1A1 (0.36) KISS1RKDM4EALDH1A1GAAHPGD
SCHEMBL3976065 0.86 GPR132 (0.37) KISS1RLMNAMAPK1
SCHEMBL3979343 0.86 SPHK2 (0.36) KDM4EMAPK1
SCHEMBL3977150 0.84 KISS1R (0.38) KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US claimed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US claimed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP claimed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 NR1H4 288/4885SIRT2 210/4885KISS1R 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.